Multiple Myeloma | Disease Landscape & Forecast | G7 | 2025
The treatment of multiple myeloma is becoming increasingly complex. Sanofi’s Sarclisa received a label expansion for the first-line treatment of autologous stem-cell transplantation-ineligible patients, in combination with bortezomib, lenalidomide, and dexamethasone. The regimen will directly compete with regimens containing Johnson & Johnson’s Darzalex or Darzalex Faspro / Darzquro. The approval of bispecific antibodies (e.g., Johnson & Johnson’s Tecvayli and Talvey, Pfizer’s Elrexfio) and the label expansion of CAR T-cell therapies (e.g., Bristol Myers Squibb / Bluebird Bio’s Abecma, Johnson & Johnson / Legend Biotech’s Carvykti) have expanded the options available for relapsed / refractory disease. GSK’s antibody-drug conjugate Blenrep and other therapies in late-phase development will, if approved, further fragment the treatment of multiple myeloma.
Questions answered
- What are the sizes of the key drug-treatable populations? How will drug-treatment rates change over the 2024-2034 forecast period?
- How will the current treatment landscape change over the forecast period, and what impact will generic entry have on the market?
- Which emerging therapies are the most promising for multiple myeloma?
- What factors are driving the growth of the multiple myeloma therapy market, and how will it evolve over the forecast period?
Product description
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
